ข่าวประชาสัมพันธ์ cardiovascular risk+Type 2 Diabetes
Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline
Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high cardiovascular risk regardless of previously having had a cardiovascular event at the start of the trial.1 Findings from two post-hoc subgroup analyses of the SUSTAIN 6 trial and one post-hoc meta-analysis of MACE in the
Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk
- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1...Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major...American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway
A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends...
Latest state-of-the-art health check-up technology comes to Thailand
—
Verita Health MahaNakhon (VMH) is introducing "Verita Wisdom", a new 360° state-of-...